Cargando…

Correction: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357778/ https://www.ncbi.nlm.nih.gov/pubmed/37460252 http://dx.doi.org/10.1136/jitc-2023-006714corr1

Ejemplares similares

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021)

Correction: Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
Publicado: (2023)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity
por: Kalim, Khalid W, et al.
Publicado: (2022)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

Author Correction: COVID-19: the vasculature unleashed
por: Teuwen, Laure-Anne, et al.
Publicado: (2020)

Author Correction: Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint
por: Gurung, Pallavi, et al.
Publicado: (2023)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)

Correction to: CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling
por: Xiu, Weigang, et al.
Publicado: (2021)

Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2020)

Correction: Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity
por: Matos, Ines, et al.
Publicado: (2013)

Correction: Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages
Publicado: (2020)

Author Correction: Association of TLR4 and TLR9 polymorphisms and haplotypes with cervical cancer susceptibility
por: Pandey, Nilesh O., et al.
Publicado: (2019)

Author Correction: TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
por: Tanaka, Yuki, et al.
Publicado: (2022)

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
por: Segovia, Mercedes, et al.
Publicado: (2019)

Correction for Zhou et al., Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target
Publicado: (2023)

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
por: Kumar, Amrendra, et al.
Publicado: (2023)

Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
por: Zheng, Bingxin, et al.
Publicado: (2018)

Correction: The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma
por: Miallot, Richard, et al.
Publicado: (2023)

Author Correction: LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
por: Liu, Yi, et al.
Publicado: (2022)

SUSE Linux 9 unleashed
por: McCallister, Mike
Publicado: (2006)

Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
por: Merino, María, et al.
Publicado: (2021)

Correction: Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment
por: Yu, Yongbo, et al.
Publicado: (2023)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
Publicado: (2021)

Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022)

Correction: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
por: Zhang, T., et al.
Publicado: (2019)

Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)

Function of PD-L1 in antitumor immunity of glioma cells
por: Lou, Yongli, et al.
Publicado: (2017)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Correction to: Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis
por: Takei, Ryohei, et al.
Publicado: (2021)

Correction: PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
Publicado: (2022)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells
por: Tan, Xiaoding, et al.
Publicado: (2023)

Correction: PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing
por: Akhmetzyanova, Ilseyar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nne0bv8bgb8b70pn9ruh9sqg4f